---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-23-000006"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2023-01-20T23:59:59+00:00"
generated_at: "2026-06-20T12:41:37.167348+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "medium"
source: SEC EDGAR
---

# Xeris Biopharma amends credit deal to allow Letter of Financial Support to Australian unit

## Summary
- Amendment No. 2 signed Jan 19, 2023; permits Xeris Pharma to issue a Letter of Financial Support to its Australian subsidiary.
- Amendment modifies Credit Agreement dated March 8, 2022, with Hayfin Services as administrative agent.
- No changes to principal, interest rate, or maturity under the existing credit facility.

## SEC filing metadata
- accession: 0001867096-23-000006
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2023-01-20T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: medium
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000006/0001867096-23-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000006/xers-20230119.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-23-000006
- JSON: https://secwatch.observer/filing/0001867096-23-000006.json
- Plain text: https://secwatch.observer/filing/0001867096-23-000006.txt

## Key facts
- Material Agreements
  Xeris Biopharma Holdings, Inc. amended Amendment No. 2 to Credit Agreement and Guaranty with Hayfin Services LLP, as administrative agent, and the lenders parties thereto (effective 2023-01-19).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Hayfin Services LLP, as administrative agent, and the lenders parties thereto
  - Effective: 2023-01-19
  source text: On January 19, 2023, Xeris Biopharma Holdings, Inc. (the “Company”) entered into Amendment No. 2 to Credit Agreement and Guaranty (“Amendment No. 2”) with Xeris Pharmaceuticals, Inc. (“Xeris Pharma”), the lenders parties thereto (the “Lenders”) and Hayfin Services LLP, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the “Agent”), to amend that certain Credit Agreement and Guaranty, dated as of March 8, 2022, as amended by Amendment No. 1 to Credit Agreement and Guaranty dated September 29, 2022 (the “Credit Agreement”), by and among the Company, Xeris Pharma, the subsidiary guarantors from time to time parties thereto, the Agent and the Lenders from time to time parties thereto.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000006/0001867096-23-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.